Skip to main content
. 2019 Jun 13;5(8):1141–1149. doi: 10.1001/jamaoncol.2019.1048

Figure 2. Antitumor Activity of Niraparib in Combination With Pembrolizumab.

Figure 2.

Responses were confirmed using Response Evaluation Criteria in Solid Tumors, version 1.1. HRD indicates homologous recombination deficiency; PD-L1, programmed death-ligand 1; tBRCAmut, tumor BRCA mutated; and tBRCAwt, tumor BRCA wild type.

aAll patients with tBRCAmut also had HRD-positive disease.